<DOC>
	<DOCNO>NCT00054340</DOCNO>
	<brief_summary>RATIONALE : Combining antithymocyte globulin combination chemotherapy donor peripheral stem cell transplantation may reduce chance develop graft-versus-host disease follow transplantation . PURPOSE : Phase I/II trial study effectiveness combine antithymocyte globulin busulfan cyclophosphamide reduce graft-versus-host disease patient undergo donor stem cell transplantation myelodysplastic syndrome myeloproliferative disorder .</brief_summary>
	<brief_title>Combination Chemotherapy Antithymocyte Globulin Reducing Graft-Versus-Host Disease Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome Myeloproliferative Disorder</brief_title>
	<detailed_description>OBJECTIVES : - Determine incidence acute graft-vs-host disease ( GVHD ) require therapy patient myelodysplastic syndrome myeloproliferative disorder treat busulfan , cyclophosphamide , anti-thymocyte globulin prior transplantation filgrastim ( G-CSF ) -mobilized peripheral blood stem cell ( bone marrow ) relate unrelated donor . - Determine incidence relapse relapse-free survival patient treat regimen . - Determine incidence non-relapse mortality day 100 1 year posttransplantation patient treat regimen . - Determine incidence Epstein-Barr virus reactivation , infection , chronic GVHD patient treat regimen . OUTLINE : This dose-escalation study anti-thymocyte globulin . - Conditioning graft-vs-host disease ( GVHD ) prophylaxis : Patients receive oral busulfan every 6 hour day -7 -4 ( 16 dos ) , cyclophosphamide IV day -3 -2 , anti-thymocyte globulin IV 3 hour day -3 , -2 , -1 . Cohorts 15 patient receive adjusted dos anti-thymocyte globulin determine optimal dose Epstein-Barr virus ( EBV ) activation GVHD reduce . The optimal dose dose 2 consecutive cohort receive regimen . - Stem cell transplantation : Patients undergo peripheral blood stem cell ( PBSC ) bone marrow transplantation day 0 . - Posttransplantation GVHD prophylaxis : Patients receive cyclosporine IV continuously day -1 4 orally twice daily day 180 . Patients also receive methotrexate day 1 , 3 , 6 , 11 . Patients follow every 6 month 2 year annually thereafter . PROJECTED ACCRUAL : A total 30-45 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Myelodysplastic syndrome ( include evolve acute myeloid leukemia ) Myeloproliferative disorder No chronic myelogenous leukemia Other disease eligible conditioning target busulfan , cyclophosphamide , antithymocyte globulin candidate study Available relate unrelated donor compatible HLAA , B , C , DRB1 , DQB1 A single allele mismatch HLAA , B , C , DRB1 allow PATIENT CHARACTERISTICS : Age 65 Performance status Not specify Life expectancy No severe limitation due disease Hematopoietic Not specify Hepatic AST great 2 time normal No hepatic disease Renal Creatinine great 2 time upper limit normal OR Creatinine clearance least 50 % age , gender , weight Cardiovascular No cardiac insufficiency require treatment No symptomatic coronary artery disease Pulmonary No severe mild hypoxemia pO_2 least 70 mm Hg DLCO least 70 % predict OR pO_2 least 80 mm Hg DLCO least 60 % predict Other Not pregnant nursing Fertile patient must use effective contraception HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy No growth factor give posttransplantation concurrently methotrexate immunosuppression Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>